Statistics from Altmetric.com
Commentary on: Derry S, Bell RF, Straube S, et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev 2019:CD007076. doi: 10.1002/14651858.CD007076.pub3.
Implications for practice and research
There is moderate quality evidence that pregabalin is more effective than placebo for postherpetic neuralgia, painful diabetic neuropathy and post-traumatic neuropathic pain.
There is no evidence to support its use in HIV neuropathy nor central neuropathic pain.
Future studies require greater sample sizes and clearer methodology.
There is a need to identify patients who would benefit from pregabalin therapy.
Pregabalin is licensed to treat neuropathic pain which is defined as pain caused by a lesion or disease of the somatosensory nervous system.1 Neuropathic pain effects up to 10% of the population2 and includes postherpetic neuralgia (PHN) and painful diabetic neuropathy (PDN). The …
Competing interests I have acted as a speaker for Pfizer for which I have received payment.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.